Pharmaceuticals

Global Eylea Industry Trends: Where the Market Is Headed by 2029

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Was The Eylea Market Worth In 2025, And What Is Its Anticipated Value By 2029?

The eylea market has demonstrated strong expansion over recent years. It is anticipated to increase from $9.94 billion in 2024 to $10.51 billion by 2025, registering a compound annual growth rate (CAGR) of 5.7%. This historical growth can be attributed to the prevalence of diabetic macular edema (DME), its clinical efficacy and safety profile, competition with other anti-VEGF therapies, approval for various retinal conditions, and a shift towards intravitreal injections.

The eylea market is projected to observe robust expansion in the forthcoming years. It is expected to attain a valuation of $13.64 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.7%. The anticipated growth during this period stems from factors such as emerging therapeutic indications, the introduction of biosimilar competition, increasing awareness and diagnosis, the availability of real-world evidence and post-market studies, and patient preference for less frequent injections. Significant trends during the forecast period are set to include advancements in imaging technologies, the rise of telemedicine and remote monitoring, the development of patient assistance programs, ongoing advances in drug delivery technologies, improvements in retinal imaging technologies, and clinical trials for new indications.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9155&type=smp

Which Industry Drivers Are Expected To Accelerate The Eylea Market From 2025 To 2029?

The rising prevalence of ocular conditions is anticipated to boost the Eylea market. Ocular diseases encompass eye impairments that hinder the eye’s proper functioning and negatively impact visual acuity and clarity. These conditions frequently present without symptoms until they have reached advanced stages. Eylea is utilized to address various ocular diseases, including wet age-related macular degeneration (AMD) and glaucoma, which cause damage to the retina or macula, thereby affecting vision. Eylea works by inhibiting the protein responsible for the development of new, weaker blood vessels and alleviating retinal swelling caused by blockages in the blood vessels. For example, in October 2022, the BrightFocus Foundation, a US-based nonprofit organization dedicated to advancing research and support for macular degeneration and glaucoma, reported that 80 million individuals worldwide were living with glaucoma, a figure projected to increase to over 111 million by the year 2040. Consequently, the growing occurrence of ocular diseases is a key driver for the Eylea market.

What Are The Key Segments In The Eylea Market?

The eylea market covered in this report is segmented –

1) By Product: Prefilled Syringe Package, Vial Package

2) By Disorder: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Other Disorders

3) By Application: Hospitals, Retail Pharmacy, Other Applications

Subsegments:

1) By Prefilled Syringe Package: Single-Dose Prefilled Syringes, Multi-Dose Prefilled Syringes

2) By Vial Package: Single-Dose Vials, Multi-Dose Vials

How Are Trends Influencing The Eylea Market?

Research and development activities represent a key trend gaining traction in the eylea market. A primary focus for the leading industry participants in eylea is the creation of innovative technical solutions. For example, in August 2023, Regeneron Pharmaceuticals, Inc., a global biotechnology company based in the US specializing in medicines for serious diseases, secured US FDA approval for Eylea HD (aflibercept) injection 8 mg. This approval is intended for patients afflicted with wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR). The treatment regimen specifies an initial period of administration every four weeks for the first three months across all indications, followed by modified intervals of every eight to 16 weeks for wAMD and DME, and every eight to 12 weeks for diabetic retinopathy.

Who Are The Prominent Global Companies Shaping The Eylea Market?

Major companies operating in the eylea market include Regeneron Pharmaceuticals Inc., Bayer AG, Novartis AG, Roche Holding AG, Pfizer Inc., Amgen Inc., Sanofi S.A., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., GlaxoSmithKline plc, Biogen Inc., Alcon Inc., Johnson & Johnson, Eli Lilly and Company, Genentech Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Samsung Bioepis Co. Ltd., Lupin Limited, Sun Pharmaceutical Industries Ltd., Zydus Cadila, Torrent Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Amneal Pharmaceuticals LLC, Apotex Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/eylea-global-market-report

Which Geographies Are Emerging As Strong Markets For The Eylea Industry?

North America was the largest region in the eylea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the eylea market during the forecast period. The regions covered in the eylea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Eylea Market Report:

https://www.thebusinessresearchcompany.com/customise?id=9155&type=smp

Browse Through More Reports Similar to the Global Eylea Market 2025, By The Business Research Company

Iot In Manufacturing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/iot-in-manufacturing-global-market-report

Power Generators Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/power-generators-global-market-report

Ventricular Assist Device Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/ventricular-assist-device-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795